Experic, a contract development and manufacturing organisation (CDMO) and clinical supply services company serving the biopharmaceutical industry, has announced the successful completion of a Series B extension round of financing.
The additional capital is earmarked to support the company's double-digit organic growth and strategic investments in key operational assets.
The funds from this round will be allocated towards additional investments in the company’s previously announced analytical laboratory and spray drying capabilities, which are critical to enhancing Experic's manufacturing capabilities.
The additional funding from seasoned life science investors in this round will enable us to expand technical capabilities and accelerate growth
- David Wood, CEO and chairman of Experic
David Wood, CEO and chairman of Experic, said: "The additional funding from seasoned life science investors in this round will enable us to expand technical capabilities and accelerate growth. This reflects the continued confidence in Experic’s business model, scientific expertise, and the client service we deliver daily."
The strategic investments facilitated by this funding round are expected to bolster Experic’s presence in the biopharmaceutical industry by expanding its service offerings and capabilities.
